Previous 10 | Next 10 |
Geron ( NASDAQ: GERN ) shares gained 6% premarket on Friday after the biopharmaceutical company priced its $198M upsized offering of 55,876,297 shares and pre-funded warrants to purchase 25M shares. The shares are being offered at $2.45 each, while the pre-funded warrants are ...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,00...
The Top 3 Factors That Impact Penny Stocks Prices Penny stocks can be a great opportunity to enjoy high returns on investments, but it is important to understand what makes them move in the market. Generally speaking, there are three primary factors that drive penny stock movement: social med...
Geron ( NASDAQ: GERN ) said it plans to offer and sell $175M shares of its common stock in an underwritten public offering. ( GERN ) is down 8.5% after the bell. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number o...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends...
Summary 2022 was a terrible year for us biotech investors. We wanted 2023 to be good, and one of the most difficult stocks out there, Geron Corporation, has paid off today. Geron posted excellent topline pivotal data from the IMERGE trial. 2023 has arrived. The year has st...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Sundry Photography / Shutterstock.com Micron (NASDAQ: MU ) stock is on the move Wednesday as one analyst believes the memory market is close to reaching its bottom . Daiwa analyst SK Kim is behind today...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Though the major indices posted a strong recovery effort on Wednesday, late-stage clinical biopharmaceutical firm Geron (NASDAQ: GERN ) soared above most public players. Following positive top-line results for its blood c...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) tried to bounce back on Wednesday morning, seeking to recover losses from the first trading day of 2023. As of shortly after the opening bell, the Nasdaq had moved up by more than half a percent. Individual stocks within the Nasdaq have seen h...
Best Penny Stocks To Buy? 7 To Watch With Big Headlines In January 2023 Are you ready to get the ball rolling with penny stocks in 2023? You’re not alone, but unlike other years, chances are we’ll see much more volatility in the stock market. Heightened concerns over inflation, ...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...